Skip to content
10-Q

Quarterly Report

ABEONA THERAPEUTICS INC. ABEO

0001493152-26-022614

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 57M sh
Shares Diluted Q1 2026 · Mar 31, 2026 56.62M sh
Shares Diluted Q1 2026 · Mar 31, 2025 49.78M sh
Capex Q1 2026 · Mar 31, 2026 $935K
Capex Q1 2026 · Mar 31, 2025 $1.4M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$19.8M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$18.4M
Long Term Debt Q1 2026 · Mar 31, 2026 $4.75M
Long Term Debt Q1 2026 · Dec 31, 2025 $7.81M
Short Term Investments Q1 2026 · Mar 31, 2026 $106.9M
Short Term Investments Q1 2026 · Dec 31, 2025 $112.97M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $61.37M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $78.44M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $15.94M
Stockholders Equity Q1 2026 · Mar 31, 2026 $144.94M
Stockholders Equity Q1 2026 · Dec 31, 2025 $159.22M
Stockholders Equity Q1 2026 · Mar 31, 2025 $41.4M
Stockholders Equity Q1 2026 · Dec 31, 2024 $44.03M
Current Liabilities Q1 2026 · Mar 31, 2026 $31.05M
Current Liabilities Q1 2026 · Dec 31, 2025 $29.57M
Total Liabilities Q1 2026 · Mar 31, 2026 $53.56M
Total Liabilities Q1 2026 · Dec 31, 2025 $60.35M
Current Assets Q1 2026 · Mar 31, 2026 $182.99M
Current Assets Q1 2026 · Dec 31, 2025 $204.91M
Total Assets Q1 2026 · Mar 31, 2026 $198.49M
Total Assets Q1 2026 · Dec 31, 2025 $219.57M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.30
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.24
Eps Basic Q1 2026 · Mar 31, 2026 −$0.30
Eps Basic Q1 2026 · Mar 31, 2025 −$0.24
Sga Expense Q1 2026 · Mar 31, 2026 $19.5M
Sga Expense Q1 2026 · Mar 31, 2025 $9.79M
Rd Expense Q1 2026 · Mar 31, 2026 $9.56M
Rd Expense Q1 2026 · Mar 31, 2025 $9.94M
Net Income Q1 2026 · Mar 31, 2026 −$17.08M
Net Income Q1 2026 · Mar 31, 2025 −$12.03M
Operating Income Q1 2026 · Mar 31, 2026 −$23.03M
Operating Income Q1 2026 · Mar 31, 2025 −$19.73M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $2.7M
Revenue Q1 2026 · Mar 31, 2026 $8.72M